Eton Pharmaceuticals, Inc. (ETON) Q4 FY25 Earnings Call

Management targets continued high-growth, margin expansion, and multiple product catalysts through 2027.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-29
Length57 minutes
EPS$0.05
EPS consensus$0.12
Revenue$21.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All ETON earnings ยท Back to ETON overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.